GW Pharmaceuticals Plc
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. 10.38%48.510.0%$558.21m
VRXValeant Pharmaceuticals International, Inc. -1.02%27.2714.1%$160.46m
CTLTCatalent, Inc. -1.56%136.012.0%$156.22m
PRGOPerrigo Co. Plc -1.11%43.796.9%$137.53m
ICLRICON plc -0.94%268.192.8%$117.70m
INDPIndaptus Therapeutics, Inc. -12.95%10.080.0%$111.65m
HZNPHorizon Therapeutics Plc 1.63%109.715.5%$103.63m
JAZZJazz Pharmaceuticals Plc 1.12%133.222.1%$97.67m
ARGXargenx SE 2.50%331.670.0%$60.05m
ENDPEndo International Plc 4.04%2.838.5%$55.42m
AXSMAxsome Therapeutics, Inc. 4.17%29.721.8%$52.84m
UTHRUnited Therapeutics Corp. -2.47%200.0814.0%$50.73m
BHCBausch Health Cos., Inc. -1.02%27.270.0%$49.51m
SNOASonoma Pharmaceuticals, Inc. 0.75%5.353.4%$33.25m
SAGESAGE Therapeutics, Inc. 2.43%46.407.6%$22.43m

Company Profile

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.